Investigational drug · Phase 3
GLS-010
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Persistent, Recurrent, or Metastatic Cervical Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
14
Any phase or sponsor naming "GLS-010"
First trial start
2022
Oct 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GLS-010", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Persistent, Recurrent, or Metastatic Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GLS-010" as an intervention, largest first.
- A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerPivotal-lookingRecruiting
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT05798819 · 424 participants (planned) · Start Apr 20, 2023 · Primary completion Dec 31, 2029
Drug: GLS-010; Placebo and 4 more · For: Persistent, Recurrent, or Metastatic Cervical Cancer
Sites: Shanghai, China
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid TumorsCompleted
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT03713905 · 293 participants · Start Jul 1, 2017 · Primary completion Feb 28, 2022
Drug: GLS-010 · For: Advanced Solid Tumors
Sites: Beijing, China
- Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung CancerStatus unknown
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT05978401 · 152 participants (planned) · Start Aug 10, 2023 · Primary completion Apr 1, 2025
Drug: GLS-012+GLS-010; GLS-012+GLS-010 and 2 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Shanghai, China
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT05688215 · 141 participants (planned) · Start Mar 7, 2023 · Primary completion Dec 31, 2027
Drug: Fluorouracil; Irinotecan and 5 more · For: Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma
Sites: Los Angeles, California
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT05909436 · 107 participants (planned) · Start Oct 31, 2022 · Primary completion Dec 2026
Drug: GLS-012; GLS-010 · For: Solid Tumor
Sites: Beijing, China
- SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)Not yet recruiting
Peking University Third HospitalAcademic, hospital or other
NCT06009029 · 96 participants (planned) · Start Aug 2023 · Primary completion Jul 2026
Drug: Zimberelimab (GLS-010) · For: Locally Advanced Pancreatic Cancer
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT03972722 · 89 participants (planned) · Start May 15, 2019 · Primary completion May 15, 2022
Drug: GLS-010 · For: Cervical Cancer
Sites: Shanghai, China
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT03655483 · 85 participants (planned) · Start Aug 24, 2018 · Primary completion Apr 11, 2021
Drug: GLS-010 · For: Classical Hodgkin's Lymphoma
Sites: Guiyang, China; Changsha, China; Chengdu, China · 5 sites in all
- GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)Pivotal-lookingStatus unknown
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT05518318 · 60 participants (planned) · Start Sep 2022 · Primary completion Jun 2025
Drug: GLS-010; Chemotherapy of Investigator's choice · For: Classic Hodgkin's Lymphoma; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
- A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT05900765 · 54 participants (planned) · Start Jun 14, 2023 · Primary completion Jun 30, 2025
Drug: Zimberelimab 240mg · For: Classical Hodgkin Lymphoma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.
Deng T, Wang F, Zhang L, et al. · Cancer Immunol Immunother 2024
- Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.
Xia L, Wang J, Wang C, et al. · Int J Gynecol Cancer 2023
- Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer.
Chen Y, Huang A, Yang Q, et al. · Front Immunol 2022
- Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.
Lin N, Zhang M, Bai H, et al. · Eur J Cancer 2022
- Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer.
Lou B, Wei H, Yang F, et al. · Front Oncol 2021
- Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Liu D, Ma C, Lu P, et al. · Eur J Cancer 2021
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.